The ISSAAC-seq protocol commences with the dual tagging of active chromatin regions, utilizing Tn5 transposase, which has become a cornerstone technique due to its efficiency and reliability. This initial phase of the workflow is crucial as it identifies regions of the genome that exhibit chromatin accessibility—an indicator of which genes may be transcriptionally active and poised for expression. By mapping these accessible regions, scientists can begin to unravel the regulatory mechanisms that dictate gene expression for specific cell types.

An essential component of the ISSAAC-seq methodology involves the generation of RNA-DNA hybrids. This is accomplished through reverse transcription, which allows the conversion of RNA into complementary DNA (cDNA). This hybridization step is a pivotal advancement, as it effectively bridges the gap between chromatin accessibility and gene expression profiling, allowing researchers to simultaneously assess both molecular layers from the same nucleus.

Following this initial tagging and hybridization, researchers have a range of options available for isolating single nuclei. The flexibility of ISSAAC-seq is evident in its compatibility with multiple single-nucleus isolation strategies. Both plate-based and droplet-based barcoding approaches can be utilized, depending on the specific needs and objectives of the study. This adaptability enhances the protocol’s versatility, making it suitable for a wide array of applications across different biological contexts.

Another remarkable feature of ISSAAC-seq is its scalability. The workflow is designed to accommodate a flexible throughput, enabling researchers to analyze anywhere from hundreds to tens of thousands of individual nuclei in a single run. This modularity is particularly advantageous for large-scale studies aimed at elucidating the heterogeneity found within complex tissue samples. By enabling high-throughput analysis, ISSAAC-seq opens new avenues for large-scale genomic studies that require robust data sets.

Notably, the robustness and sensitivity of the ISSAAC-seq methodology ensure that the resultant data generated is of high quality for both chromatin accessibility and gene expression. In the global context of genomic research, high-quality data is fundamental for drawing reliable conclusions and advancing our understanding of cellular behaviors and interactions. The coherent nature of the data produced through this dual-modality approach enhances the interpretative power of subsequent analyses.

The entire ISSAAC-seq workflow is impressively streamlined, allowing it to be completed within just one to two days. This rapid turnaround time is a significant advantage, especially for laboratories that operate in fast-paced research environments. By reducing the time required for sample preparation and data collection, researchers can focus on the downstream analysis and interpretation of their results, ultimately accelerating the pace of discovery in molecular biology.

As the scientific community continues to appreciate the importance of heterogeneity in cell populations—particularly within the context of development, disease, and therapeutic response—the ability to simultaneously profile chromatin and gene expression is increasingly invaluable. The insights gleaned from ISSAAC-seq will undoubtedly inform researchers about the cell type-specific regulatory mechanisms that govern gene expression, highlighting potential targets for therapeutic interventions.

Moreover, the potential applications of ISSAAC-seq extend far beyond basic research. Understanding chromatin accessibility and gene expression dynamics at the single-cell level carries implications for fields such as cancer research, where the heterogeneity of tumor cells can significantly impact treatment outcomes. The ability to profile both aspects concurrently may unveil crucial insights into how tumors adapt and respond to therapy, paving the way for more personalized treatment strategies.

In addition to its application in cancer research, ISSAAC-seq can be harnessed to investigate various other biological questions, including developmental biology, neurobiology, and immunology. As scientists strive to delineate the complex regulatory networks that control cellular function and fate, the dual profiling afforded by ISSAAC-seq provides a powerful tool for understanding the multifaceted nature of cellular regulation.

Looking ahead, researchers anticipate that the widespread adoption of ISSAAC-seq will catalyze a paradigm shift in how cellular biology is approached. The integration of chromatin accessibility and gene expression data at the single-nucleus level is set to become a foundational component of cellular profiling, enabling a deeper understanding of the molecular underpinnings of diverse biological phenomena.

In conclusion, ISSAAC-seq represents a significant step forward in the quest to understand cellular complexity. By allowing researchers to assess chromatin dynamics and gene expression in tandem, this innovative protocol promises to enhance our understanding of the molecular mechanisms that drive cell fate decisions across a range of biological contexts. As the field progresses, it is expected that ISSAAC-seq will continue to yield crucial insights, informing future research directions and therapeutic innovations.

Subject of Research: Multimodal profiling of chromatin accessibility and gene expression.

Article Title: Single-nucleus chromatin accessibility and gene expression co-profiling by ISSAAC-seq.

Article References:

Xu, W., Hu, Y., Zhang, Y. et al. Single-nucleus chromatin accessibility and gene expression co-profiling by ISSAAC-seq.
Nat Protoc (2026). https://doi.org/10.1038/s41596-025-01304-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-025-01304-y

Keywords: Chromatin accessibility, Gene expression, Single-cell analysis, ISSAAC-seq, Molecular profiling, Cellular heterogeneity.

At its core, single-cell RNA sequencing (scRNA-seq) is a technique that captures and analyzes RNA transcripts from individual cells. This offers a granular perspective on the transcriptome, which refers to the complete set of RNA transcripts produced by the genome at any given time. By examining RNA at the single-cell level, scientists can unveil the unique expression profiles that define different cell types and states. This sharp focus on individual cells allows for a more nuanced understanding of molecular functions and interactions that contribute to overall organismal behavior.

One of the pioneering studies in this domain demonstrated the revolutionary potential of scRNA-seq. The advent of microfluidic technologies has paved the way for high-throughput analysis, enabling researchers to process thousands of individual cells in a single experiment. This innovation was not merely a technical improvement; it marked a paradigm shift in our understanding of biological systems. The capacity to isolate and analyze single cells dramatically enhances our ability to investigate cellular responses to various stimuli, thereby augmenting our comprehension of developmental biology, immunology, and oncology.

However, the technical challenges inherent in single-cell RNA sequencing cannot be overlooked. Capturing high-fidelity data from single cells necessitates a meticulous approach to library preparation, amplification, and sequencing. Contaminated samples, low RNA yield, and biased amplification can lead to inaccuracies, complicating data interpretation. Researchers are continuously refining protocols to enhance the robustness and reliability of scRNA-seq, striving to minimize sources of variability that can confound results.

The bioinformatics landscape surrounding single-cell data analysis is equally complex. The sheer volume of data generated poses significant computational challenges. Sophisticated algorithms are required to process, analyze, and interpret these datasets effectively. To extract meaningful insights, researchers employ methods such as clustering, dimensionality reduction, and differential expression analysis. Each step in the analysis pipeline is critical to deciphering the intricate patterns of gene expression among heterogeneous cell populations.

Additionally, scRNA-seq holds promise beyond basic research; it is heralded as a transformative tool for clinical applications. For example, understanding the transcriptomic profiles of tumor cells offers potential biomarkers for diagnosis and treatment responsiveness in cancer therapies. As medicine moves towards more personalized approaches, scRNA-seq can inform the design of tailored therapeutic strategies by elucidating the molecular underpinnings of disease at the cellular level.

The application of scRNA-seq is not limited to human biology. In ecology, researchers are harnessing single-cell transcriptomics to explore microbial communities and their responses to environmental changes. This frontier of research is critical in addressing ecological issues such as climate change and biodiversity loss. By diving into the molecular mechanisms that drive microbial interactions, scientists can better understand ecosystem dynamics and resilience.

Despite its promise, the integration of single-cell transcriptomics with other omics technologies remains a frontier yet to be fully explored. Combining scRNA-seq with single-cell proteomics or metabolomics can provide a more comprehensive view of cellular function. Integrative multi-omics approaches will likely deliver transformative insights, enabling a systems-level understanding of cellular behavior and fostering breakthroughs in various scientific disciplines.

Emerging from the shadows of traditional paradigms, single-cell RNA transcriptomics is now at the forefront of research innovation. Institutions worldwide are investing heavily in the development of this technology, fostering a wave of discoveries and generating collaborative multidisciplinary initiatives. As techniques advance and protocols are refined, we can expect to witness an explosion of applications that leverage the unique capabilities of scRNA-seq.

Addressing ethical considerations surrounding single-cell research is paramount. As we delve deeper into the intricacies of life at the cellular level, it is crucial to contemplate the ramifications of our discoveries. Discussions surrounding privacy, consent, and potential implications of manipulating cellular processes must accompany technological advancements. The scientific community bears a responsibility to tread carefully, ensuring that the quest for knowledge is balanced with a commitment to ethical integrity.

The narrative of single-cell RNA transcriptomics is intrinsically linked to the relentless pursuit of understanding the living world. As researchers peel back the layers of complexity that characterize biological systems, we inch closer to unraveling the secrets of life itself. Future generations of scientists will undoubtedly expand upon the foundations laid by early pioneers, propelling the field into exciting new territories.

In summary, single-cell RNA transcriptomics is more than just a technique; it is a revolutionary approach that empowers researchers to explore the intricate details of gene expression and cellular function. By elucidating the unique identities of individual cells, we are equipped to confront complex biological questions that have long eluded scientists. As we continue to refine methodologies and expand our computational capabilities, the potential for transformative discoveries in biology and medicine will only grow.

The journey ahead in single-cell transcriptomics is filled with challenges, but it is also rich with opportunity. We remain on the cusp of a new era in understanding life, armed with powerful technologies and an unyielding desire to decode the biological world. In this age of single-cell analysis, the possibilities for groundbreaking research and clinical advancements are limited only by our imagination and ingenuity.

As we embrace the future of single-cell RNA transcriptomics, it is essential to remain committed to collaboration across disciplines. The intersection of technology, biology, and ethics will shape the trajectory of our discoveries, shaping how we understand and engage with life at the most fundamental level.

Subject of Research: Single-cell RNA transcriptomics

Article Title: Establishing single cell RNA transcriptomics: a brief guide

Article References:

Cole, A.G. Establishing single cell RNA transcriptomics: a brief guide.
Front Zool 22, 25 (2025). https://doi.org/10.1186/s12983-025-00579-x

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12983-025-00579-x

Keywords: Single-cell RNA sequencing, transcriptomics, gene expression, bioinformatics, clinical applications, ethical considerations, molecular biology.

Alzheimer’s disease prevalence in African Americans is nearly twice that found in White or European-ancestry groups residing in the United States. While social determinants such as healthcare disparities, educational inequality, diagnostic bias, and increased cardiovascular and metabolic comorbidities contribute to this disparity, the genetic architecture underlying AD risk in African Americans has remained elusive. Prior gene expression studies predominantly focused on mixed or European-ancestry cohorts, often marginalizing African American participants, thus limiting statistical power to identify population-specific molecular changes.

This new research addresses this glaring gap by analyzing post-mortem brain tissue from 207 African American donors—comprising 125 individuals with pathologically confirmed AD and 82 cognitively normal controls. The tissue originated from the prefrontal cortex, a brain region critically involved in higher-order cognition and severely impacted in Alzheimer’s pathology. By deploying cutting-edge gene expression profiling technologies, the researchers quantitatively assessed the activity of thousands of genes, uncovering a suite of differentially expressed genes, many of which had previously not been associated with AD.

Among the most striking discoveries was the elevated expression of ADAMTS2, a gene encoding an extracellular matrix metalloproteinase, found at approximately 1.5 times higher levels in AD brains compared to controls. This finding held robust statistical significance and was corroborated by analysis of an independent dataset derived from a larger sample of European-ancestry individuals, verifying that ADAMTS2 upregulation is a shared hallmark of Alzheimer’s pathology across ethnicities.

The convergence of ADAMTS2 as the top-ranked gene in both populations is unprecedented in AD genetic research. It implicates common biological mechanisms driving neurodegeneration, suggesting that despite diverse genetic backgrounds and environmental exposures, fundamental pathogenic pathways may be conserved. ADAMTS2’s role in remodeling the brain’s extracellular matrix could influence amyloid plaque deposition or synaptic integrity, positing it as a compelling target for therapeutic development.

Leading the study, Dr. Lindsay A. Farrer emphasized the significance of these cross-population findings: “The overlap in gene expression changes points towards universal biological processes in AD progression. This offers hope for developing treatments with broad efficacy while underscoring the importance of including diverse populations in genetic research to capture the full spectrum of disease biology.”

The implications of population-specific versus shared genetic risk factors are profound. While many AD risk variants exhibit varying frequencies or exclusive associations within different ancestries, identifying genes like ADAMTS2 that transcend these boundaries advances the field toward unified models of neurodegeneration. It also highlights the necessity of expanding genomic studies in underrepresented groups to ensure equitable biomedical advancements.

This extensive project was undertaken with specimens sourced from 14 NIH-funded Alzheimer’s Disease Research Centers nationwide, ensuring a robust and geographically diverse sample of African American brain tissue. The methodological rigor entailed pathologically verifying diagnosis and implementing sophisticated statistical models to control for confounding factors intrinsic to post-mortem transcriptional analyses, such as RNA integrity and cellular composition.

Further analyses revealed that the molecular pathways influenced by the identified gene set encompass not only extracellular matrix remodeling but also neuroinflammation, synaptic signaling, and metabolic regulation. These interconnected pathways offer a multi-layered framework for understanding how genetic perturbations contribute to the clinical manifestations of AD, potentially informing biomarker development and stratified therapeutic interventions.

This study is among the first to deliver a high-resolution portrait of gene expression disturbances in African American Alzheimer’s brains, setting a precedent for future inclusion of diverse populations in neuroscience research. It paves the way for investigating whether modulating ADAMTS2 expression or function can mitigate disease progression or cognitive decline.

Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the findings mark a critical stride toward enhancing the representation of African Americans in genetic studies and aspire to reduce health disparities. The work was meticulously supported by multiple NIH grants and state-level research awards, with strict adherence to ethical standards and discrete conflict of interest disclosures, underscoring the scientific integrity of the investigation.

Given the disproportionate impact of AD on African Americans and the complex interplay of genetic and social factors, this research underscores an urgent call for broader, more inclusive scientific inquiry. Such efforts promise not only to elucidate AD’s pathobiology more comprehensively but to unlock novel avenues for diagnosis and therapy that could benefit all affected populations.

In conclusion, the identification of ADAMTS2 as a consistently dysregulated gene across diverse ancestral groups invigorates the search for shared molecular triggers underpinning Alzheimer’s neurodegeneration. It invites a paradigm shift toward integrative genetic research that embraces population diversity as fundamental rather than auxiliary, ultimately contributing to equitable health outcomes and precision medicine in neurodegenerative diseases.

Subject of Research: Cells

Article Title: Novel differentially expressed genes and multiple biological pathways for Alzheimer’s disease identified in brain tissue from African American donors

News Publication Date: 8-Oct-2025

Web References: medrxiv.org/content/10.1101/2024.11.12.24317218v1

References: Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, DOI: 10.1002/alz.70629

Keywords: Health and medicine

Neuroblastoma, originating from immature nerve cells, predominantly affects infants and young children. Despite advances in surgical techniques, chemotherapy regimens, and stem cell therapies, the prognosis for high-risk neuroblastoma remains grim, with survival rates stubbornly below 60%. This dismal outlook stems in part from the tumor’s notorious heterogeneity and the current scarcity of reliable biomarkers that can stratify patients effectively, guiding precision therapies.

Traditional molecular markers such as MYCN amplification and ALK mutations, while clinically informative, cover only subsets of patients and often require intricate or expensive testing methodologies. These limitations have spurred an urgent quest for more universally applicable and interpretable prognostic signatures. The recent study answers this call by integrating vast sequencing datasets with cutting-edge computational approaches, revealing a richer molecular tapestry of neuroblastoma.

At the heart of this research is an enhanced spatial temporal Support Vector Machine (stSVM) algorithm, adeptly applied to bulk RNA sequencing (RNA-seq) data from over 1,200 neuroblastoma patients. This machine learning model sifted through thousands of gene expression profiles to identify 528 genes tightly correlated with patient survival outcomes. This expansive gene set offers a panoramic view of the genetic drivers underlying disease aggressiveness.

To distill actionable biomarkers from this extensive gene pool, the team employed Weighted Gene Co-expression Network Analysis (WGCNA), a method that elucidates patterns of gene co-regulation and pinpoints central “hub” genes driving network behavior. This refined analysis spotlighted 11 hub genes with outsized influence on neuroblastoma biology: AURKA, BLM, BRCA1, BRCA2, CCNA2, CHEK1, E2F1, MAD2L1, PLK1, RAD51, and notably, RFC3.

Among these, RFC3 emerged as a particularly compelling prognostic marker. Elevated expression of RFC3 was strongly associated with poor patient survival and intriguingly linked to suppressed natural killer (NK) cell activity, suggesting a tumor mechanism of immune evasion. This finding hints that RFC3 might not simply be a bystander gene but an active participant in sculpting the tumor microenvironment to favor cancer progression.

Beyond correlating gene expression with clinical outcomes, the study probed how these hub genes influence responsiveness to chemotherapy drugs routinely used in neuroblastoma treatment. Intriguingly, tumors exhibiting high RFC3 levels demonstrated increased sensitivity to vincristine and cyclophosphamide, two cornerstone agents in pediatric oncology protocols. This dual prognostic and predictive utility positions RFC3 as a potential biomarker to both assess risk and guide therapeutic choices.

To deepen their mechanistic understanding, the researchers also examined single-cell RNA sequencing (scRNA-seq) data, allowing resolution of gene expression at the level of individual tumor and immune cells. This granular analysis confirmed elevated RFC3 expression predominantly in epithelial and myeloid cell subpopulations of patients with poorer survival outcomes. Moreover, these patients exhibited reduced infiltration of CD8+ T cells, another critical component of the anti-tumor immune response. Such immune profiling provides valuable insight into the interplay between tumor genetics and host immunity.

The study’s integrative pipeline—combining machine learning, bulk and single-cell transcriptomics, immune profiling, and co-expression network analysis—exemplifies modern systems biology approaches applied to pediatric cancer research. This multidisciplinary methodology uncovers complex molecular interdependencies that traditional statistical analyses frequently overlook, offering a more holistic view of neuroblastoma pathobiology.

Dr. Yupeng Cun, senior investigator on the project, highlights the transformative potential of this research: “Our comprehensive approach reveals novel biomarkers like RFC3 that not only predict clinical outcomes but also indicate likely responses to standard chemotherapy agents. By fusing computational models with multi-omics data, we uncover molecular patterns that can ultimately enhance patient stratification and individualized treatment.”

These findings mark an important milestone for precision medicine in childhood cancers. As a biomarker, RFC3 stands out for its multifaceted role—informing prognosis, reflecting immune landscape alterations, and hinting at chemotherapy responsiveness. Clinicians in the future could leverage RFC3 expression to identify high-risk neuroblastoma patients early, tailoring treatment intensity and monitoring strategies accordingly to improve survival chances.

Furthermore, the platform developed by this research team could be adapted to other aggressive cancers, expanding its impact beyond neuroblastoma to benefit a broader spectrum of oncologic diseases. Continued work integrating additional omics layers—such as proteomics and epigenomics—and further experimental validation will be vital to translating these insights into clinical tools.

This study underscores the growing importance of artificial intelligence and machine learning technologies in decoding cancer complexity. By revealing genetic architects of neuroblastoma and their relationships with the immune system and drug sensitivity, researchers are stepping closer to conquering a formidable pediatric malignancy that has long evaded definitive prognostic clarity.

As the field progresses, personalized oncology for children with neuroblastoma may soon incorporate biomarkers like RFC3 as routinely measured clinical tools. These advances promise not only improved risk assessment but also more nuanced, effective therapeutic regimens that minimize toxicity and maximize survival—a long-sought goal in pediatric cancer care.

The promise held by such integrative, AI-driven biomarker discovery efforts ignites hope that tailored treatments could markedly improve outcomes, sparing children unnecessary side effects while targeting their tumors with precision. For families confronting neuroblastoma, these advances bring new optimism fueled by the power of genomic medicine and computational innovation.

In sum, this pioneering research not only reveals critical molecular insights but also charts a pragmatic path toward clinical application, heralding a new era of prognostic sophistication and treatment personalization in pediatric neuroblastoma.

Subject of Research:
Not applicable

Article Title:
Identification of Prognostic Biomarkers in Gene Expression Profile of Neuroblastoma Via Machine Learning

News Publication Date:
27-May-2025

Web References:
http://dx.doi.org/10.1002/pdi3.70009

References:
10.1002/pdi3.70009

Image Credits:
Pediatric Discovery

Keywords:
Neuroblastoma, Pediatric Oncology, Machine Learning, Biomarkers, Gene Expression, RFC3, Immune Evasion, Chemotherapy Sensitivity, Single-cell RNA Sequencing, Weighted Gene Co-expression Network Analysis, Precision Medicine